Physician profile
Stephanie Marie Rodriguez
NPI 1770134751
$159,315.73
in general payments reported to CMS, 2019-2025
46 companies · $105K in 2025
The $105K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,456 · 2022: $2,383 · 2023: $2,743 · 2024: $46K · 2025: $105K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $130K · Travel and Lodging: $14K · Food and Beverage: $10K · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $130,305.00 |
| Travel and Lodging | $14,021.04 |
| Food and Beverage | $10,105.03 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $145,655.27 | 2021-2025 | |
| Novo Nordisk INC | $2,454.81 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Corcept Therapeutics | $1,660.74 | 2021-2025 | Korlym |
| Lilly USA, LLC | $1,420.85 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Medtronic, INC. | $733.94 | 2022-2025 | Minimed 780g, Turbohawk, Synchromedii |
| Nevro Corp. | $695.79 | 2021-2024 | Senza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $651.64 | 2021-2025 | Jardiance, Tradjenta, Synjardy |
| Sanofi-Aventis U.S. LLC | $570.19 | 2021-2024 | |
| Amgen INC. | $565.73 | 2021-2025 | Repatha, Tepezza, Repatha |
| Novartis Pharmaceuticals Corporation | $542.36 | 2022-2025 | |
| Madrigal Pharmaceuticals | $440.76 | 2024-2025 | Rezdiffra, Resmetirom |
| Dexcom, INC. | $427.97 | 2021-2024 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $412.47 | 2023-2025 | Recorlev, Gvoke Hypopen |
| Bayer Healthcare Pharmaceuticals INC. | $379.88 | 2023-2025 | |
| Esperion Therapeutics, INC. | $294.50 | 2021-2025 | Nexletol |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recordati_rare_diseases_inc. | $250.54 | 2024-2025 | Isturisa, Signifor Lar |
| Antares Pharma, INC. | $244.78 | 2021-2023 | Xyosted, Nocdurna, Tlando |
| Amarin Pharma, INC. | $219.88 | 2021-2022 | |
| Abbott Laboratories | $209.63 | 2022-2025 | Freestyle Libre |
| Teva Pharmaceuticals USA, INC. | $125.00 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $124.90 | 2022 | |
| Merck Sharp & Dohme LLC | $107.77 | 2021-2024 | Keytruda |
| Neurocrine Biosciences, INC. | $85.96 | 2024-2025 | |
| Glaxosmithkline, LLC. | $83.00 | 2022-2025 | Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals Lp | $82.01 | 2021-2023 | Farxiga |
| Insulet Corporation | $75.56 | 2022-2025 | Omnipod |
| Amneal Pharmaceuticals LLC | $71.38 | 2025 | Unithroid |
| Ascendis Pharma Endocrinology INC | $67.04 | 2025 | Yorvipath |
| Intercept Pharmaceuticals, INC. | $64.42 | 2022 | |
| Ibsa Pharma INC. | $56.66 | 2023-2025 | Tirosint, Licart, Licart |
| Terumo Medical Corporation | $55.79 | 2022 | |
| Cardiovascular Systems INC. | $53.77 | 2022 | |
| Boston Scientific Corporation | $52.77 | 2025 | Watchman Access System, Watchman Flx |
| Ascensia Diabetes Care US INC. | $52.25 | 2023-2024 | |
| Averitas Pharma INC. | $47.84 | 2023 | Qutenza |
| Tandem Diabetes Care, INC. | $46.62 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Relievant Medsystems, INC. | $37.86 | 2023 | Intracept |
| Beta Bionics, INC. | $33.52 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Sequel Med Tech, LLC | $31.99 | 2025 | Twiist |
| Chiesi USA, INC. | $22.53 | 2024 | Mycapssa |
| Halozyme INC | $22.19 | 2023 | |
| Alexion Pharmaceuticals, INC. | $19.09 | 2023 | |
| Endo Pharmaceuticals INC. | $19.08 | 2021 | |
| Pfizer INC. | $17.57 | 2025 | |
| Henry Schein, INC. | $16.83 | 2024 | |
| Cequr Corporation | $10.60 | 2023 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Rodriguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.